We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Merck KGaA (PK) | USOTC:MKKGY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.37 | -1.14% | 32.07 | 31.41 | 32.40 | 32.23 | 31.77 | 31.77 | 32,298 | 21:31:55 |
By Colin Kellaher
Merck KGaA (MRK.XE) Wednesday said the U.S. Food and Drug Administration granted breakthrough-therapy designation to its tepotinib investigational therapy in a form of lung cancer.
The Darmstadt, Germany, science and technology company said the designation covers tepotinib in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping alterations who progressed following platinum-based cancer therapy.
The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug may show substantial improvement over available therapies.
Lung cancer is one of the most common types of cancer worldwide. Merck said alterations of the MET signaling pathway are found in 3% to 5% of non-small cell lung cancer cases and correlate with aggressive tumor behavior and poor clinical prognosis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 11, 2019 06:34 ET (10:34 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Merck KGaA (PK) Chart |
1 Month Merck KGaA (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions